Content Types

Posts

  • New day for antibody-drug conjugates – Chemical & Engineering News
  • What makes a good antibody–drug conjugate? – Martin De Cecco, Daniel N. Galbraith & Lisa L. McDermottt
  • Beacon Targeted Therapies announces the launch of Beacon Oncolytic Viruses
  • Cell Therapy 2.0
  • Overcoming Challenges in the Development of Anticancer ADCs
  • Immuno-oncology cell therapies: commercial considerations and strategies for the new decade
  • Beacon Targeted Therapies announces the launch of Beacon Gene Therapy
  • Frontiers in Oncology – Perspective: Designing T-Cell Engagers With Better Therapeutic Windows
  • Hot Topics at CAR-TCR 2020
  • Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials
  • TCR Therapies Summit 2020 Magazine
  • Drug developers take fresh aim at ‘guided-missile’ cancer drugs
  • CAR-TCR Europe Summit 2020 Magazine
  • World ADC London 2020 Magazine
  • Innate Killer Summit 2020 Magazine
  • From Mylotarg to Polivy: Ebbs and flows, successes and woes of ADCs
  • Trends & Forecasts – Tenacious ADCs
  • World ADC San Diego Magazine 2019
  • Biomarkers for Checkpoint Inhibition and Their Clinical Utility – Timothy James Fabisiak, B.A.
  • Bispecific antibodies: a mechanistic review of the pipeline Aran F. Labrijn, Maarten L. Janmaat, Janice M. Reichert & Paul W. H. I. Parren
  • Beacon Targeted Therapies Launches Beacon Adoptive Cell
  • The Evolving Shape of the ADC Market: The Widening Application of ADCs and Manufacturing Improvements Meeting Demand – Charlie Johnson, CEO of ADC Bio, adcbio.com
  • Antibodies to watch in 2019 – Hélène Kaplon & Janice M. Reichert

    • Pages

  • Webinar Resources
  • Internal Comms
  • Our data charter
  • FAQS
  • Advanced Keyword Searches
  • News
  • Solutions
  • Request a demo
  • About
  • Contact
  • Events
  • Who’s it for?
  • Privacy Policy
  • Resource Center
  • Site Map
  • Terms & Conditions
  • Home

    • Solutions

  • Beacon Cell Therapy
  • Beacon Biomarkers & Assays
  • Beacon Immune Tolerance
  • Beacon Microbiome
  • Beacon RNA
  • Beacon Cytokine
  • Beacon Cancer Vaccine
  • Beacon TPD
  • Beacon DDR
  • Beacon Oncolytic Viruses
  • Beacon Gene Therapy
  • Beacon Checkpoint
  • Beacon Bispecific
  • Beacon ADC

    • Events

  • 7th CAR-TCR Europe Summit 2024
  • 3rd mRNA-Based Therapeutics Summit Europe 2024
  • 8th Microbiome Movement – Drug Development Europe 2024
  • 7th DDR Inhibitors Summit 2024
  • Cell Therapy for Autoimmune Disease Summit
  • 14th World Bispecifics Summit 2023
  • 8th Oncolytic Virotherapy Summit 2023
  • 6th Targeted Protein Degradation Summit
  • mRNA Cancer Vaccines Summit 2023
  • 13th World Clinical Biomarkers & CDx Summit
  • 8th CAR-TCR Summit 2023
  • 4th Annual Gamma Delta T Therapies Summit 2023
  • 14th World ADC San Diego 2023
  • 3rd mRNA-Based Therapeutics Summit
  • 5th Gene Therapy for Neurological Disorders Summit 2023
  • 8th Microbiome Movement – Drug Development Summit
  • 5th Annual Allogeneic Cell Therapies Summit
  • 5th Treg Summit
  • 4th STING & TLR Targeting Therapies Summit
  • 4th Cytokine-Based Drug Development Summit
  • 2nd LNP Formulation & Process Development Summit
  • 5th Cell Engager Summit
  • 6th Neoantigen Summit Europe

    • Webinars

  • More Information Coming Early 2024
  • The ADC Boom: Navigating the Expansive Landscape of Antibody-Drug Conjugates
  • More Information Coming Early 2024
  • More Information Coming Early 2024
  • The Future of Cell Therapies: An In-Depth Analysis of the 2023 Commercial and Research Landscape
  • Unlocking the Value of Microbiome-Targeting Therapeutics in Combating Infectious Diseases
  • Bispecific Antibodies and Immune Checkpoint Modulators: A H1 Landscape Analysis
  • Realizing the Full Potential within the RNA and Gene Therapy Landscapes: 2023 So Far
  • Examining the Cytokine-Based Drug Development Landscape: Interleukins and Beyond
  • T Cell Therapies: The Road Ahead for Addressing Autoimmune Indications
  • The TPD Disease Landscape: Oncology vs. Non-Oncology
  • Gene Therapy: Optimizing the Safety of Viral Vectors
  • The DDR Landscape: The Past, Present & Future
  • Beacon Cancer Vaccine Webinar 2022
  • DDR Webinar 2022
  • Oncolytic Viruses Webinar 2021
  • Gene Therapy Webinar 2021
  • Adoptive Cell Webinar 2021
  • Oncolytic Viruses Webinar 2020
  • Bispecific Webinar 2020
  • ADC Webinar 2020
  • Gene Therapy Webinar 2020

    • Infographics

  • Beacon Gene Therapy: 2023 ASH Annual Meeting Abstracts
  • Monoclonal Antibodies (mAbs) Unveiled: A Comprehensive Review of the Landscape in Immune-Mediated Diseases Report 2023
  • Beacon TPD: ASH Pre-Conference Planner 2023
  • RNA SITC Post-Conference Report 2023
  • Infographic 2023 Oncolytic Viruses ESMO Abstracts Analysis
  • The Rise of Bispecific Combination Trials Infographic
  • Beacon DDR: ESMO Post-Conference Report 2023
  • Beacon TPD: ESMO Post-Conference Report 2023
  • Cytokine: ESMO Congress 2023 Abstracts
  • Checkpoint: ESMO Congress 2023 Abstracts
  • Infographic 2023 Cancer Vaccine ESMO Abstracts Analysis
  • DDR AACR NCI EORTC Pre-Conference Planner 2023
  • Beacon TPD: Next Generation Degraders Infographic
  • Editing Technologies Report 2023
  • The Checkpoint Disease Landscape: Exploring the Top Cancer Indications
  • The Preclinical Cytokine Review: An Analysis of the Latest Data
  • The Oligonucleotide Landscape Digest
  • SITC 2023 Cancer Vaccine Annual Meeting Abstracts
  • SITC 2023 Oncolytic Viruses Annual Meeting Abstracts
  • Allergies Report 2023
  • SITC 2023 Cell Therapy Annual Meeting Abstracts
  • Infographic 2023 Unlocking the Potential of mRNA Cancer Vaccines
  • The DDR Combination Therapies Infographic
  • The 2023 H1 RNA Landscape Review
  • The H1 2023 Cytokine Landscape Review
  • H1 2023 Oncolytic Viruses Landscape Review
  • The H1 2023 DDR Landscape Review
  • H1 2023 Cancer Vaccine Landscape Review
  • The H1 2023 ADC Landscape Review
  • The H1 2023 Checkpoint Landscape Review
  • The H1 2023 Bispecific Landscape Review
  • The H1 2023 Microbiome Landscape Review
  • The 2023 H1 TPD Landscape Review
  • H1 2023 Cell Therapy Landscape Review
  • H1 2023 Gene Therapy Landscape Review
  • H1 2023 Immune Tolerance Landscape Review
  • Cancer Vaccine: Exploring Human Papillomavirus Infographic
  • ADC Preclinical Development: Where are we in 2023?
  • Gene Therapy: Lysosomal Storage Diseases – A Comprehensive Overview
  • Report 2023 Oncolytic Viruses Monotherapies vs Combinations
  • Checkpoint: The Adenosine-Pathway Clinical Trial Landscape
  • Bispecific: Landscape Review of Checkpoint-Targeting Bispecifics
  • TPD: ASCO 2023 Infographic
  • Microbiome: Milestones Infographic
  • Adoptive Cell: ASCO Annual Meeting 2023 Abstracts
  • Cytokine: ASCO Annual Meeting 2023 Abstracts
  • Bispecific: ASCO Annual Meeting 2023 Abstracts
  • ADC: ASCO Annual Meeting 2023 Abstracts
  • DDR ASCO Post-Conference Report 2023
  • RNA: ASCO Post-Conference Report 2023
  • Oncolytic Viruses ASCO Post-Conference Report 2023
  • Cancer Vaccine ASCO Post-Conference Report 2023
  • Beacon Search v. AI Thought Piece
  • RNA: ASGCT Annual Meeting 2023 Abstracts
  • AACR 2023: ADC Highlights and Insights
  • Cytokine & Adoptive Cell: Cytokine-Armored Cell Therapies
  • Checkpoint: ASCO Annual Meeting 2023 Abstracts
  • RNA: mRNA-Based Therapeutics Infographic
  • Oncolytic Viruses: ASGCT Annual Meeting 2023 Abstracts
  • Adoptive Cell: ASGCT Annual Meeting 2023 Abstracts
  • Gene Therapy: ASGCT Annual Meeting 2023 Abstracts
  • Cancer Vaccine Infographic 2023
  • Microbiome: Preclinical Models Infographic
  • Cytokine: AACR Annual Meeting 2023 Abstracts
  • ADC: AACR Annual Meeting 2023 Abstracts
  • Checkpoint: AACR Annual Meeting 2023 Abstracts
  • Bispecific: AACR Annual Meeting 2023 Abstracts
  • RNA: AACR Annual Meeting 2023 Abstracts
  • Oncolytic Viruses: AACR Annual Meeting 2023 Abstracts
  • Cancer Vaccine: AACR Annual Meeting 2023 Abstracts
  • Adoptive Cell: AACR Annual Meeting 2023 Abstracts
  • DDR: AACR Annual Meeting 2023 Abstracts
  • TPD: AACR Annual Meeting 2023 Abstracts
  • The 2022 Cytokine Landscape Review
  • The 2022 Checkpoint Landscape Review
  • The 2022 ADC Landscape Review
  • The 2022 Bispecific Landscape Review
  • The 2022 DDR Landscape Review
  • The 2022 RNA Landscape Review
  • The 2022 TPD Landscape Review
  • The 2022 Cancer Vaccine Landscape Review
  • The 2022 Oncolytic Viruses Landscape Review
  • The 2022 Adoptive Cell Landscape Review
  • The 2022 Microbiome Landscape Review
  • TPD – The Molecular Glue Landscape: A Review
  • The 2022 Gene Therapy Landscape Review
  • Checkpoint: The TIGIT Axis Targeted Cancer Clinical Trial Landscape
  • Cytokine: A Spotlight on the TGF-β Cancer Clinical Trial Landscape
  • RNA-Targeted Drug Discovery Presentation 2022
  • TPD ASH Post-Conference Report 2022
  • DDR ASH Post-Conference Report 2022
  • Microbiome SITC Post-Conference Report 2022
  • Beacon Gene Therapy – The Eye Disorder Landscape
  • TPD ASH Pre-Conference Planner 2022
  • Cancer Vaccine Infographic 2022
  • RNA SITC Post-Conference Report 2022
  • DDR ASH Pre-Conference Planner 2022
  • Adoptive Cell: SITC Pre-conference Planner 2022
  • 5th Annual TPD Summit Presentation
  • Microbiome: GI and Metabolic Diseases Infographic
  • Cancer Vaccine: SITC Pre-conference Planner 2022
  • Oncolytic Viruses: SITC Pre-conference Planner 2022
  • RNA: The Current Landscape of Lipid Nanoparticles for Drug Delivery Planner
  • ADC: SITC Pre-Conference Planner 2022
  • Checkpoint: SITC Pre-Conference Planner 2022
  • Bispecific: SITC Pre-Conference Planner 2022
  • Cytokine: SITC Pre-Conference Planner 2022
  • DDR ESMO Infographic 2022
  • Adoptive Cell: ESMO Post-Conference Report 2022
  • Cancer Vaccine: ESMO Post-Conference Report 2022
  • Oncolytic Viruses ESMO Post-Conference Report 2022
  • Bispecific: ESMO Post-Conference Report 2022
  • Checkpoint: ESMO Post-Conference Report 2022
  • ADC: ESMO Post-Conference Report 2022
  • Cytokine: ESMO Post-Conference Report 2022
  • Beacon Gene Therapy – Clinical Holds in the AAV Space
  • RNA: Mid-Year Landscape Review
  • Checkpoint: Mid-Year Landscape Review 2022
  • DDR: Mid-Year Landscape Review
  • Bispecific: Mid-Year Landscape Review 2022
  • ADC: Mid-Year Landscape Review 2022
  • Cytokine: Mid-Year Landscape Review 2022
  • Microbiome: Mid-Year Landscape Review
  • Oncolytic Viruses: Mid-Year Landscape Review 2022
  • TPD: Mid-Year Landscape Review 2022
  • Cancer Vaccine: Mid-Year Landscape Review 2022
  • The mRNA Landscape and Beyond Presentation
  • Gene Therapy: Mid-Year Landscape Review 2022
  • Adoptive Cell: Mid-Year Landscape Review 2022
  • 4-1BB Landscape Review: Shift Towards a Bispecific Therapeutics Approach
  • ASCO 2022: ADC Highlights and Insights
  • ASCO 2022: Bispecific Highlights and Insights
  • Cancer Vaccine ASCO Post-Conference Report 2022
  • The Oligonucleotide Landscape and Beyond Presentation
  • Adoptive Cell ASCO Post-Conference Report 2022
  • Oncolytic Viruses ASCO Post-Conference Report 2022
  • TPD ASCO Post-Conference Report 2022
  • Microbiome Movement Drug Development Presentation
  • Checkpoint ASCO Post-Conference Report 2022
  • Cytokine ASCO Post-Conference Report 2022
  • Bispecific ASCO Post-Conference Report 2022
  • DDR ASCO Post-Conference Report 2022
  • ADC ASCO Post-Conference Report 2022
  • Oncolytic Viruses – Vaccinia Virus Analysis
  • Adoptive Cell – Manufacturing Challenges & Considerations for Allogeneic Cell Therapy
  • Adoptive Cell ASGCT Post-Conference Report 2022
  • Gene Therapy ASGCT Post-Conference Report 2022
  • Cancer Vaccine ASCO Pre-Conference Planner 2022
  • TPD Beacon Podcast Ep.1
  • DDR ASCO Pre-Conference Planner 2022
  • Gene Therapy ASGCT Pre-Conference Planner 2022
  • RNA ASGCT Pre-Conference Planner 2022
  • TPD ASCO Pre-Conference Planner 2022
  • Cytokine ASCO Pre-Conference Planner 2022
  • Bispecific ASCO Pre-Conference Planner 2022
  • Checkpoint ASCO Pre-Conference Planner 2022
  • RNA AACR Post-Conference Planner 2022
  • ADC ASCO Pre-Conference Planner 2022
  • Oncolytic Viruses ASCO Pre-Conference Planner 2022
  • Adoptive Cell ASCO Pre-Conference Planner 2022
  • The Thriving Interleukin Therapies Landscape
  • DDR AACR Infographic 2022
  • The CD73 Cancer Clinical Trial Landscape
  • Adoptive Cell AACR Post-Conference Report 2022
  • Oncolytic Viruses AACR Post-Conference Report 2022
  • Cancer Vaccine AACR Post-Conference Report 2022
  • TPD AACR Post-Conference Report 2022
  • Cytokine AACR Post-Conference Report 2022
  • Bispecific AACR Post-Conference Report 2022
  • ADC AACR Post-Conference Report 2022
  • Checkpoint AACR Post-Conference Report 2022
  • The RNA Landscape and Beyond Presentation
  • Gene Therapy AAV Durability Report
  • RNA AACR Pre-Conference Planner 2022
  • Adoptive Cell AACR Pre-Conference Planner 2022
  • Cancer Vaccine AACR Pre-Conference Planner 2022
  • Checkpoint AACR Pre-Conference Planner 2022
  • Bispecific AACR Pre-Conference Planner 2022
  • Cytokine AACR Pre-Conference Planner 2022
  • ADC AACR Pre-Conference Planner 2022
  • TPD AACR Pre-Conference Planner 2022
  • Oncolytic Viruses AACR Pre-Conference Planner 2022
  • DDR AACR Pre-Conference Planner 2022
  • RNA Infographic 2022
  • Landscape Reviews

    • Archives

    Categories

  • ADC
  • Advanced Therapies Webinar
  • Antibodies and Biologics Webinar
  • Bispecific
  • Cancer Vaccine
  • Cell Therapy
  • Checkpoint
  • Cytokine
  • DDR
  • Gene Therapy
  • Immune Tolerance
  • Infographic
  • Infographic
  • Microbiome
  • Oncolytic Viruses
  • Report
  • RNA
  • Small Molecules Webinar
  • TPD
  • Uncategorized
  • Upcoming Webinars
  • Webinar
    • logo